Autism: the point of view from fragile X studies.
Fragile X gives a clear gene-brain map that flags hidden autism and points to treatable traits.
01Research in Context
What this study did
The authors looked at fragile X syndrome (FXS) and asked: can this single-gene disorder teach us about autism?
They read all the FXS papers they could find and wrote a story-style review.
They compared the clear biology of FXS with the fuzzier behavioral picture of autism.
What they found
FXS is not the main cause of autism, but it gives a clean map of brain-gene links.
That map can guide future autism studies, because FXS shows which brain paths to test.
How this fits with other research
McGonigle et al. (2014) extends this idea by counting heads: half of kids with FXS meet autism research rules, yet only a quarter get an autism clinic label.
The 2014 paper shows the field still misses many autism cases inside FXS, so the clean model has messy real-world use.
Zhu et al. (2025) moves past modeling and tries a pill—metformin—for FXS behavior.
Their mixed results say the FXS model is ready for treatment trials, not just theory.
Together, the three papers trace a line: 1998 sets the model, 2014 finds under-diagnosis, 2025 tests a drug.
Why it matters
If you assess kids with autism or FXS, treat FXS as a red flag for systematic autism screening.
Use the FXS brain map to pick target behaviors like social avoidance or hyperactivity.
Start metformin only after baseline data, and track hyperactivity and sleep as early wins.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Add the FXS question to your intake form; if yes, run an autism screener even if no diagnosis exists.
02At a glance
03Original abstract
The relationship between the fragile X syndrome (FXS) and autism is reviewed. Shortly after the FXS was first described, it was noted that certain behaviors commonly found in afflicted individuals resemble certain features of autism. Research concerning a possible relationship between these conditions is summarized. The outcome of this research indicates that FXS is not a common cause of autism, although the number of individuals with FXS who meet diagnostic criteria for autism is higher than can be accounted for by chance. The major focus of this paper highlights that FXS is a well-defined neurogenetic disease that includes a cognitive behavioral phenotype, and has both a known biological cause and an increasing well-delineated pathogenesis. Autism is a behaviorally defined syndrome whose syndromic boundaries and biological causes are not known. These profound differences complicate comparisons and causal discussions. However, the behavioral neurogenetic information available about FXS suggests certain pathways for future research directed at elucidating the syndrome of autism.
Journal of autism and developmental disorders, 1998 · doi:10.1023/a:1026000404855